Stay updated with breaking news from Bioe holdings inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Biological E India s next Serum, Bharat Biotech of COVID-19 vaccine The acquisition of Akorn India helped Biological E create a potential overall manufacturing capacity of over 1 billion doses per annum. PB Jayakumar | June 2, 2021 | Updated 23:07 IST Providence will provide necessary technology transfer for Biological E to manufacture mRNA vaccines in India. The oldest Indian private vaccine maker, Hyderabad-based Biological E Limited, is emerging as a domestic powerhouse of COVID-19 vaccine manufacturing following its latest deal with Canada-based biotech company Providence Therapeutics. In addition to the Providence deal, Biological E currently has a couple of in-house COVID-19 vaccines under development and another major manufacturing contract agreement for Johnson & Johnson s single-dose COVID-19 vaccine. It was among the earliest Indian companies to tap potential COVID-19 vaccine opportunities. ....
OSIF inks licence agreement with Biological E for COVID-19 vaccine technology OSIF inks licence agreement with Biological E for COVID-19 vaccine technology 14 December 2020 | News BE will be responsible for the evaluation and further development, including the commercialisation of the vaccine candidate(s) Source credit: Shutterstock Biological E Limited (BE), a Hyderabad-based vaccine & pharmaceutical company, and the Ohio State Innovation Foundation (OSIF), US announced the execution of an exclusive license agreement for a COVID-19 vaccine technology. OSIF has licensed novel live attenuated measles virus vectored vaccine candidates against SARS-CoV-2, which were developed by the Ohio State University College of Veterinary Medicine, exclusively to (BE). ....